Literature DB >> 15537645

Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization.

Michael J Wichroski1, Kozi Ichiyama, Tariq M Rana.   

Abstract

To study how HIV-1 viral infectivity factor (Vif) mediates proteasome-dependent depletion of host factor APOBEC3G, functional and nonfunctional Vif-APOBEC3G interactions were correlated with subcellular localization. APOBEC3G localized throughout the cytoplasm and co-localized with gamma-tubulin, 20 S proteasome subunit, and ubiquitin at punctate cytoplasmic bodies that can be used to monitor the Vif-APOBEC3G interaction in the cell. Through immunostaining and live imaging, we showed that a substantial fraction of Vif localized to the nucleus, and this localization was impaired by deletion of amino acids 12-23. When co-expressed, Vif exhibited more pronounced localization to the cytoplasm and reduced the total cellular levels of APOBEC3G but rarely co-localized with APOBEC3G at cytoplasmic bodies. On the contrary, Vif(C114S), which is inactive but continues to interact with APOBEC3G, stably associated with APOBEC3G in the cytoplasm, resulting in complete co-localization at cytoplasmic bodies and a dose-dependent exclusion of Vif(C114S) from the nucleus. Following proteasome inhibition, cytoplasmic APOBEC3G levels increased, and both proteins co-accumulated nonspecifically into a vimentin-encaged aggresome. Furthermore in the presence or absence of APOBEC3G, Vif localization was significantly altered by proteasome inhibition, suggesting that aberrant localization may also contribute to the loss of Vif function. Finally mutations at Vif Ile(9) disrupted the ability of Vif or Vif(C114S) to coimmunoprecipitate and to co-localize with APOBEC3G, suggesting that the N terminus of Vif mediates interactions with APOBEC3G. Taken together, these results demonstrate that cytoplasmic Vif-APOBEC3G interactions are required but are not sufficient for Vif to modulate APOBEC3G and can be monitored by co-localization in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15537645     DOI: 10.1074/jbc.M408048200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Authors:  Mawuena Binka; Marcel Ooms; Myeika Steward; Viviana Simon
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

3.  Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Authors:  Erez Pery; Ann Sheehy; N Miranda Nebane; Andrew Jay Brazier; Vikas Misra; Kottampatty S Rajendran; Sara J Buhrlage; Marie K Mankowski; Lynn Rasmussen; E Lucile White; Roger G Ptak; Dana Gabuzda
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

4.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

5.  Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Authors:  Craig Pace; Jean Keller; David Nolan; Ian James; Silvana Gaudieri; Corey Moore; Simon Mallal
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 6.  Advances in the structural understanding of Vif proteins.

Authors:  Pierre Barraud; Jean-Christophe Paillart; Roland Marquet; Carine Tisné
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

7.  Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization.

Authors:  Mark D Stenglein; Hiroshi Matsuo; Reuben S Harris
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  Feline Immunodeficiency Virus Vif N-Terminal Residues Selectively Counteract Feline APOBEC3s.

Authors:  Qinyong Gu; Zeli Zhang; Lucía Cano Ortiz; Ana Cláudia Franco; Dieter Häussinger; Carsten Münk
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

9.  Cellular microRNA and P bodies modulate host-HIV-1 interactions.

Authors:  Robin Nathans; Chia-Ying Chu; Anna Kristina Serquina; Chih-Chung Lu; Hong Cao; Tariq M Rana
Journal:  Mol Cell       Date:  2009-06-26       Impact factor: 17.970

10.  Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.

Authors:  Sandra Kao; Ritu Goila-Gaur; Eri Miyagi; Mohammad A Khan; Sandrine Opi; Hiroaki Takeuchi; Klaus Strebel
Journal:  Virology       Date:  2007-09-06       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.